retatrutide clinical trial phase retatrutide New 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Lilly's triple agonist, retatrutide, delivered

Ozempic Doses Chart This Ozempic dose chart explains the safe weekly dosing schedule, how doses increase over time, and what each treatment stage is designed to achieve

Eli Lilly is running a direct head-to-head trial comparing the two drugs (NCT06662383, 800 patients)

It requires understanding what separates genuine research-grade retatrutide from the questionable material flooding the market

Alzheimers Dement (2020) 16(9):131229

THEREFORE, clinical trial designers, investors, and regulators need to aim for more #clinicallyrelevant treatment target #endpoints beyond large magnitude wt loss, and also develop various drug #doses for the diverse intended populations and their different needs over time on their #weightmanagement journey

Together, these compounds address weight management while potentially preserving lean mass during significant fat loss